Zevenbergen Capital Investments LLC Increases Stock Holdings in DexCom, Inc. (NASDAQ:DXCM)

Zevenbergen Capital Investments LLC boosted its stake in shares of DexCom, Inc. (NASDAQ:DXCM) by 9.6% in the fourth quarter, according to its most recent disclosure with the SEC. The firm owned 387,168 shares of the medical device company’s stock after acquiring an additional 34,020 shares during the period. Zevenbergen Capital Investments LLC owned about 0.10% of DexCom worth $30,110,000 at the end of the most recent quarter.

A number of other large investors also recently added to or reduced their stakes in the stock. Congress Wealth Management LLC DE boosted its stake in shares of DexCom by 865.3% in the fourth quarter. Congress Wealth Management LLC DE now owns 169,338 shares of the medical device company’s stock worth $13,170,000 after acquiring an additional 151,796 shares during the last quarter. Simplify Asset Management Inc. acquired a new stake in shares of DexCom in the fourth quarter valued at about $8,197,000. KLP Kapitalforvaltning AS purchased a new position in shares of DexCom in the fourth quarter worth about $10,476,000. TD Private Client Wealth LLC boosted its position in DexCom by 62.8% during the fourth quarter. TD Private Client Wealth LLC now owns 433 shares of the medical device company’s stock worth $34,000 after acquiring an additional 167 shares during the last quarter. Finally, Teacher Retirement System of Texas grew its position in shares of DexCom by 269.4% in the fourth quarter. Teacher Retirement System of Texas now owns 28,759 shares of the medical device company’s stock valued at $2,237,000 after purchasing an additional 20,974 shares in the last quarter. 97.75% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity at DexCom

In other DexCom news, EVP Jereme M. Sylvain sold 2,090 shares of the company’s stock in a transaction that occurred on Wednesday, January 29th. The stock was sold at an average price of $86.91, for a total transaction of $181,641.90. Following the sale, the executive vice president now owns 83,526 shares in the company, valued at $7,259,244.66. This represents a 2.44 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link. Also, CEO Kevin R. Sayer sold 33,359 shares of the stock in a transaction on Wednesday, January 29th. The stock was sold at an average price of $86.91, for a total transaction of $2,899,230.69. Following the sale, the chief executive officer now directly owns 319,037 shares in the company, valued at $27,727,505.67. This trade represents a 9.47 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 105,009 shares of company stock valued at $8,044,178. Insiders own 0.30% of the company’s stock.

Wall Street Analyst Weigh In

Several analysts have issued reports on DXCM shares. Citigroup upped their target price on DexCom from $101.00 to $104.00 and gave the company a “buy” rating in a report on Tuesday, March 4th. Wells Fargo & Company reaffirmed an “overweight” rating on shares of DexCom in a research report on Saturday, March 8th. Baird R W raised DexCom from a “hold” rating to a “strong-buy” rating in a research note on Thursday, January 16th. Robert W. Baird raised DexCom from a “neutral” rating to an “outperform” rating and upped their price target for the company from $86.00 to $104.00 in a report on Thursday, January 16th. Finally, Morgan Stanley increased their target price on shares of DexCom from $75.00 to $82.00 and gave the company an “equal weight” rating in a research report on Friday, February 14th. Four research analysts have rated the stock with a hold rating, thirteen have given a buy rating and two have issued a strong buy rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $99.82.

DexCom Price Performance

Shares of NASDAQ DXCM opened at $73.80 on Monday. The company has a debt-to-equity ratio of 0.59, a current ratio of 1.47 and a quick ratio of 1.28. DexCom, Inc. has a 1-year low of $62.34 and a 1-year high of $142.00. The business has a 50-day moving average of $83.33 and a 200-day moving average of $77.03. The company has a market capitalization of $28.84 billion, a price-to-earnings ratio of 51.61, a PEG ratio of 2.30 and a beta of 1.28.

DexCom (NASDAQ:DXCM) last released its quarterly earnings results on Thursday, February 13th. The medical device company reported $0.45 earnings per share for the quarter, missing analysts’ consensus estimates of $0.50 by ($0.05). DexCom had a net margin of 14.29% and a return on equity of 30.14%. On average, equities analysts anticipate that DexCom, Inc. will post 2.03 EPS for the current fiscal year.

DexCom Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.